On the cusp of their nuptials, Celsus Therapeutics plc and its betrothed, Volution Immuno Pharmaceuticals SA, attracted more guests to their party. Read More
Omeros Corp. (NASDAQ:OMER) shares rose to a record high Tuesday, climbing 72 percent overall to close at $25.03 after the company said OMS721, a therapy it’s developing for the treatment of thrombotic microangiopathies (TMAs), continued to perform well in a small midstage trial. Read More
LONDON – A charity formed by senior academics from across the UK to tackle the problem of antimicrobial resistance (AMR) is announcing its first research program Wednesday. Read More
Breaking the body’s immune tolerance to tumors has been the biggest advance for cancer treatment in recent years. Now, scientists have reported that the same strategy might be successful against neurodegenerative diseases. Read More
DUBLIN – Norway’s Prime Minister Erna Solberg helped focus a spotlight on Norway’s emerging oncology cluster this week by performing the official opening of the Oslo Cancer Cluster Innovation Park, the first stage in an ambitious program to bring together in a single setting a critical mass in cancer research, education and cancer-related commercial biotechnology. Read More
Mylan NV, of Hertfordshire, UK, received an FDA warning letter citing conditions at three of its drug manufacturing facilities in Bangalore, India, including two that were part of its 2013 acquisition of Agila Specialties. Read More
Benitec Biopharma Ltd., of Sydney, priced its U.S. IPO of 1.5 million American depositary shares (ADSs), representing 30 million fully paid ordinary shares of Benitec and warrants to purchase another 500,000 ADSs, or 10 million fully paid ordinary shares, at $9.21 apiece per ADS and 1 cent per warrant, for expected gross proceeds of $13.8 million. Read More
strong>Portage Biotech Inc., of Toronto, said subsidiary Biohaven Pharmaceutical Holding Co. Ltd. acquired worldwide intellectual property rights to a portfolio of more than 300 glutamate-modulating prodrugs owned by ALS Biopharma LLC, of Doylestown, Pa., for an undisclosed amount, expanding the company’s plans to develop a portfolio of compounds for diseases where aberrations in glutamate function have been implicated in the pathophysiology of the underlying illness. Read More
Bavarian Nordic A/S, of Copenhagen, said it started a phase I study of its MVA-BN RSV vaccine candidate against respiratory syncytial virus (RSV). The trial, being conducted in the U.S., will evaluate the safety, tolerability and immunogenicity of a recombinant MVA-BN-based RSV vaccine in 63 healthy adults, ages 18 to 65. Read More
